)
Visual
test
Xilio Therapeutics
Xilio Therapeutics (XLO) investor relations material
Xilio Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary23 Mar, 2026
Executive summary
Advanced XTX501, a bispecific PD-1/masked IL-2, toward IND submission in mid-2026 and Phase 1 initiation in H2 2026.
Progressed multi-specific masked T cell engager programs targeting PSMA/STEAP1 and CLDN18.2, with new preclinical data to be presented at AACR 2026.
Extended cash runway through end of 2027, supported by recent financings and milestone payments.
Financial highlights
Cash and cash equivalents rose to $137.5M as of Dec 31, 2025, from $55.3M a year earlier.
Collaboration and license revenue was $13.7M for Q4 2025 (vs $1.7M Q4 2024) and $43.8M for FY 2025 (vs $6.3M FY 2024), driven by AbbVie and Gilead agreements.
R&D expenses increased to $18.1M in Q4 2025 (vs $8.8M Q4 2024) and $56.0M for FY 2025 (vs $41.2M FY 2024), reflecting pipeline advancement.
Net income of $10.4M in Q4 2025 (vs net loss of $13.1M Q4 2024); net loss of $35.0M for FY 2025 (vs $58.2M FY 2024).
Total assets at year-end 2025 were $154.7M, with stockholders' equity of $35.3M.
Outlook and guidance
Cash runway expected through end of 2027, excluding potential future milestone or warrant proceeds.
IND submissions for masked T cell engager programs targeting PSMA/STEAP1 and CLDN18.2 planned for 2027.
Initial Phase 1 data for XTX501 anticipated in H2 2027, pending IND clearance.
Efarindodekin alfa Phase 2 data package for Gilead expected in H1 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Xilio Therapeutics
- Announced a dual-targeted PSMA/STEAP1 cell engager with CD3 masking, IND planned for 2027.XLO
Leerink Global Healthcare Conference 20269 Mar 2026 - Stockholders to vote on a reverse stock split to help maintain Nasdaq listing and flexibility.XLOProxy Filing26 Jan 2026
- Tumor-selective immunotherapies advance with major clinical and platform data expected in Q4.XLOMorgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026
- Vote sought on a reverse stock split to maintain Nasdaq listing and enhance share marketability.XLOProxy Filing16 Jan 2026
- Vilastobart plus atezolizumab shows early efficacy and low toxicity in MSS-CRC and cold tumors.XLOStudy Update15 Jan 2026
- Strong pipeline progress, AbbVie deal, and improved financials extend cash runway into 2026.XLOQ4 202414 Jan 2026
- Vilastobart showed 27% response in MSS CRC; $52M AbbVie deal extends cash runway into Q1 2026.XLOQ1 202514 Jan 2026
- A 27% response rate was achieved in MSS-CRC patients without liver metastases.XLOStudy Update9 Jan 2026
- Promising tumor-activated therapies show strong early efficacy and safety in solid tumors.XLOTD Cowen 45th Annual Healthcare Conference26 Dec 2025
Next Xilio Therapeutics earnings date
Q1 202614 May, 2026
Xilio Therapeutics
Next Xilio Therapeutics earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage